Aristopharma

What Aristopharma does

Aristopharma Ltd is a privately held Bangladeshi pharmaceutical manufacturer founded in 1986 and headquartered in Dhaka. It is ranked among the top 10 pharmaceutical companies in Bangladesh and manufactures approximately 300–400 medicines across broad therapeutic categories including cardiovascular, anti-diabetic, ophthalmology, oncology, antibiotics, gastroenterology, respiratory, NSAIDs, and herbal products. The company serves patients in Bangladesh through a field sales force of approximately 3,000 medical representatives and a distribution network of 27 depots with ~1,200 distribution staff and cold-chain capability, and exports to 30+ countries across 5 continents. Its ophthalmic brand, Aristovision, has held the No. 1 position in the Bangladesh ophthalmic market continuously since 2006.

The company's production platform spans two manufacturing plants: the original Shampur, Dhaka facility (163,000 sq. ft.) and the Gachha, Gazipur facility (66,000 sq. ft., built 2010) built to UK MHRA standards with dedicated cephalosporin, ophthalmic, and oncology plants. Key imported technologies include Weiler (USA) Blow-Fill-Seal for preservative-free single-unit-dose ophthalmics, Glatt (Germany) fluid bed processing and auto-spray coating, and tri-layer tablet compression. Recent product launches span high-complexity biologics and biosimilars — Bevacizumab biosimilar (Bevaris), Rituximab (Rituris), Tirzepatide pre-filled syringe (Wikijet), and Resmetirom (Livheal) — alongside a 2022-launched Herbal Division. The ophthalmic facility received EU GMP approval in 2025, and the company operates under WHO cGMP across all plants.

Revenue is generated through one-time prescription pharmaceutical product sales to domestic and international distributors, healthcare providers, and patients; pricing is not publicly disclosed. The company is founder/management-controlled, led by Chairman & Managing Director M. A. Hassan, with no disclosed institutional investors, funding rounds, or M&A activity.

Name

Aristopharma

Legal name

Aristopharma Ltd

Website

https://aristopharma.com

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Aristopharma Ltd is a privately held top-10 Bangladeshi pharmaceutical manufacturer founded in 1986, producing ~300 brands across cardiovascular, diabetes, ophthalmic, oncology, and herbal therapeutics for domestic patients and exports to 30+ countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Generic pharmaceutical manufacturing
• Ophthalmic medicines
• Oncology therapeutics
• Cardio-diabetic formulations
• Biotech pharmaceuticals

Headquarters

HQ city

Dhaka

HQ country

Bangladesh

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and selling quality medicines at affordable prices in Bangladesh and export markets. Products include pharmaceutical formulations across wide therapeutic classes including antiulcerants, antibiotics, NSAIDs, cardiovasculars, antidiabetics, steroids, and sophisticated products like Insulin, Inhalers, Anti-Cancer drugs, and biotech products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Aristopharma manufactures and sells approximately 300 pharmaceutical brands spanning multiple therapeutic classes including cardiovascular, antidiabetic, ophthalmic, oncology, gastroenterology, antibiotics, NSAIDs, respiratory, and herbal products. Operations are supported by two manufacturing plants in Bangladesh producing tablets, capsules, injectables, inhalers, ophthalmic solutions (including preservative-free single-unit dosages via Blow-Fill-Seal technology), lyophilized injections, pre-filled syringes, and biotech products such as Insulin and monoclonal antibodies (Bevacizumab, Rituximab).

Product overview

Aristopharma Ltd is a top 10 pharmaceutical company in Bangladesh manufacturing around 300 quality brands across diverse therapeutic classes. The portfolio includes cardiovascular products (Duoblock, Empaglif, Ivacard, Renvista, SabiCard), diabetes medications (Linaglip-M, Triflo, Wikijet, Wikitin), ophthalmic products (Optimox Eye Drop, Systear, Drylief, Taflan SUD, Cyporin DS, Cozopt SUD, Betaxol, Aristopin), gastroenterology medications (Rabe, Emep MUPS, Itopa-50, Vonofix, Sodipic), antibiotics (Afix, Lizox, Zavicef), oncology drugs (Bevaris, Rituris, Palbociclib), respiratory products (Asmalin Plus, Budison-FG, Montril, Docopa), orthopedic/pain management (Naburel, Joinflex-M, Adronic), and nutritional supplements (Fosibon-DK, Neobion, Tocogel, Cutin, Cozyten, Acufer, Ferijet). The company also has a dedicated herbal division and manufactures biotech products including insulin. Key manufacturing facilities include ophthalmic, cephalosporin, inhaler, lyophilized injection, and pre-filled syringe plants, with EU GMP approval for ophthalmic manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• Aristovision: Aristopharma's ophthalmic division that has completed its successful journey of 20 years in Bangladesh pharma market and has held the No. 1 position in the BD ophtha market since 2006.

Products and services

• Pharma Products Wide range of branded generic pharmaceutical formulations including antiulcerants, antibiotics, NSAIDs, steroids, and other essential medicines manufactured at Aristopharma's plants in Shampur and Gachha, Gazipur. Targeted at physicians, hospitals, clinics, and pharmaceutical distributors in Bangladesh and 30+ export markets.
• Ophthalmic Products (Aristovision) Dedicated ophthalmic division Aristovision manufacturing ocular lubricants, anti-infective eye drops, anti-glaucoma preparations, steroid combinations, and preservative-free single-unit-dosage formulations using Blow-Fill-Seal technology. EU GMP certified facility. Has held the No. 1 position in Bangladesh's ophthalmic market since 2006. Products include Systear, Drylief, Taflan SUD, Cyporin DS, Cozopt SUD, Optimox, Betaxol, Aristopin, and Dexalev.
• Cardio-Diabetic Products Cardiovascular and antidiabetic branded formulations including SGLT2 inhibitors (Empaglif), DPP-4 inhibitors (Linaglip-M, Wikitin), dual GLP-1/GIP analogues (Wikijet), fixed-dose combinations (Duoblock, Temcard-A, Empaglif-M), sacubitril/valsartan (SabiCard), ivabradine (Ivacard), and resmetirom (Livheal) for NASH/MASH. Targeted at cardiologists, diabetologists, and endocrinology specialists.
• Oncology Products Anti-cancer biologics and chemotherapeutics including biosimilar monoclonal antibodies Bevacizumab (Bevaris) for various cancers, Rituximab (Rituris) for Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Rheumatoid Arthritis, and zoledronic acid (Adronic 4) for osteoporosis. Manufactured in dedicated oncology plant within the Gachha, Gazipur campus.
• Herbal Products Dedicated herbal product range manufactured at a WHO-cGMP compliant herbal plant within the Gazipur factory campus, including Fibosyl Powder, Arulina-500 (Spirulina), Hepamarin-140 (Silymarin), Joinflex-40, Anseng-500 (Panax ginseng), Ginkgo-B 60, and Primrole. Also encompasses Black Seed Oil (Blaksid) softgel and herbal cough formulations like Ivycof and Pepelif.
• Biotech Products Biopharmaceutical products including Insulin, monoclonal antibody biosimilars (Bevacizumab, Rituximab), and pre-filled syringe injectables manufactured at a dedicated biotech facility in the Gazipur plant. Targeted at hospitals, oncology centers, and patients requiring advanced biologic therapies.

Quantifiable outcome

• No.1 market position in Bangladesh ophthalmic market since 2006
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Incepta Pharmaceuticals: One of the fastest-growing Bangladesh pharma manufacturers, focused on specialty generics, biotech, and export markets. Competes directly with Aristopharma in cardiology, oncology, and biotech.
• Square Pharmaceuticals: Bangladesh's largest pharmaceutical manufacturer. Same product categories (cardio, diabetic, oncology, ophthalmic, biotech), same domestic distribution dynamics, and similar export ambitions — the most direct comparable to Aristopharma.
• Healthcare Pharmaceuticals: Bangladesh pharma manufacturer with growing focus on specialty care, oncology, and biotech. Comparable in product mix and export ambitions to Aristopharma.
• Renata Limited: Bangladesh's leading animal health and specialty pharmaceutical company, with a strong domestic and emerging export footprint. Comparable in therapeutic breadth and Bangladesh market positioning.
• Beximco Pharmaceuticals: Top-3 Bangladesh pharma player with strong export presence and a broad specialty/generic portfolio, including biosimilars. Comparable in scale, therapeutic breadth, and export strategy to Aristopharma.
• ACI Limited (Pharma Division): Diversified Bangladeshi conglomerate with a sizable pharma division spanning branded generics, specialty care, and biotech. Overlaps with Aristopharma across most therapeutic categories and competes in the same domestic market.
• Drug International Limited: Bangladesh-based pharmaceutical company manufacturing generics and specialty products, including ophthalmics. Competes directly with Aristopharma in Bangladesh's domestic market.

Broad incumbents

• Dr. Reddy's Laboratories: Large Indian generic and specialty pharma player with global operations including biosimilars. Comparable therapeutic breadth and export footprint — relevant incumbent benchmark for Aristopharma's expansion ambitions.
• Cipla: Major Indian pharma with strong respiratory, oncology, and specialty portfolios and a sizable emerging-markets presence. Useful comparable for Aristopharma's inhaler/respiratory and specialty aspirations.
• Sun Pharmaceutical Industries: India's largest specialty pharma company with a strong ophthalmology franchise. Closest large-cap analog to Aristopharma's specialty-generic and ophthalmic-led strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/ltdaristopharma

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aristopharma